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A B S T R A C TThe objective of this article was to provide a framework for under-
standing the different deﬁnitions of the term “personalized medicine.”
The term personalized medicine is used regularly but interpreted in
different ways. This article approaches the term by starting with a
broad view of clinical medicine, where three components can be
distinguished: the questions (e.g., what is the diagnosis?), the methods
used to answer them (e.g., a test), and the available actions (e.g., to give
or not give a particular drug). Existing deﬁnitions of personalized
medicine disagree about which questions, methods, and actions fall
within its domain. Some deﬁne the term narrowly, referring to the use
of a diagnostic test to predict drug response, thereby clarifying
whether or not a patient will beneﬁt from that drug. An example of
this combination is the HER2/neu test to predict the effectiveness of
trastuzumab in breast cancer. Many who adopt this deﬁnition asso-
ciate the concept of personalized medicine with ﬁelds such as
genetics, genomics, and other types of “-omics.” In contrast, others
view personalized medicine as a concept that has always existed,
because medicine has always considered the needs of the individual.
One deﬁnition of personalized medicine that accommodates bothsee front matter Copyright & 2013, International S
r Inc.
1016/j.jval.2013.06.005
rest: The authors have indicated that they have n
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ondence to: W. Ken Redekop, Erasmus Universit
, The Netherlands.interpretations is “the use of combined knowledge (genetic or other-
wise) about a person to predict disease susceptibility, disease prog-
nosis, or treatment response and thereby improve that person’s
health.” This predictive ability can increase over time through inno-
vations in various technologies, resulting in further improvements in
health outcomes. Moreover, these developments can lead to a better
understanding of the underlying causes of disease, which can even-
tually lead to breakthroughs in the treatment of individual patients. In
that sense, a truly personalized form of medicine can also be seen as
an ideal, a goal that will be achieved only after multiple advances in
science. Although the term personalized medicine was rechristened
somewhat recently, our ability to personalize medicine will continue
to advance in unimaginable ways as we come to learn more about the
heterogeneity that exists among individuals and diseases.
Keywords: companion diagnostic, diagnostic test, individualized medi-
cine, personalized medicine, pharmacogenetics, stratiﬁed medicine.
Copyright & 2013, International Society for Pharmacoeconomics and
Outcomes Research (ISPOR). Published by Elsevier Inc.Introduction
The term “personalized medicine” is used widely in the media
and in health care. However, people mean different things when
they use the term and do not always realize that others might
view the term very differently. The lack of one uniform deﬁnition
only increases the risk of miscommunication. This article aims to
shed some light on the general concept of personalized medicine
by teasing out and examining its different components.
Personalized Medicine: What Is It Exactly?
The interest in the term personalized medicine has grown lately,
partly because drugs are rarely 100% effective and safe and partly
because of developments such as the Human Genome Project [1].
These developments have made it possible to identify subtypes of
various diseases on the basis of genetics in addition to other means
such as histology, an ability that many believe will lead to an
improved capacity to prevent and treat various diseases. For exam-
ple, knowledge of genetics could help to determine whether patientswith certain disease subtypes are more likely than others to be
responsive to a particular drug (both old and new). On the face of it,
there seems to be agreement about what personalized medicine
entails. Further examination of the existing deﬁnitions of personal-
ized medicine, however, reveals important disparities among them.
For example, personalized medicine has been deﬁned as1.oc
o c
y,“a medical model that proposes the customization of health-
care, with decisions and practices being tailored to the
individual patient by use of genetic or other information.” [2]2. “the tailoring of medical treatment to the speciﬁc character-
istics of each patient. [It] does not literally mean the creation of
drugs or medical devices that are unique to a patient. Rather, it
involves the ability to classify individuals into subpopulations
that are uniquely or disproportionately susceptible to a partic-
ular disease or responsive to a speciﬁc treatment.” [1]3. “a form of medicine that uses information about a person’s
genes, proteins, and environment to prevent, diagnose, and
treat disease.” [3]iety for Pharmacoeconomics and Outcomes Research (ISPOR).
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deﬁnitions are sufﬁcient enough to illustrate how much existing
deﬁnitions of personalized medicine vary. The Wikipedia deﬁni-
tion refers to the customization of health care, where the actions
taken are tailored to meet the needs of the individual patient. The
President’s Council starts with a similar statement, but then
explicitly refers to the classiﬁcation of individuals into subpopu-
lations. Last, the National Cancer Institute deﬁnition refers to the
type of information as well as three speciﬁc goals of personalized
medicine (to prevent, diagnose, and treat).
A Bottom-Up Approach to Medical Decision Making
One approach to an article on the deﬁnition of a term would be to
discuss the merits and shortcomings of existing deﬁnitions and
argue in favor of one of them. For this article, however, we have
opted to take a bottom-up approach by examining what is
typically involved in patient care. This involves a brief review of
three basic elements in medical decision making: some general
questions in patient care that can be answered by using medical
tests, the ways in which they can be answered, and the medical
decisions that can be taken with these answers.
Frequently Asked Questions That Can Be Answered by Using
Medical Tests
The left-hand part of Table 1 shows a list of general types of
questions, ranging from the prediseased phase to the later stages
of disease. While this list is not exhaustive, it is complete enough
to illustrate the points to be made here.
One of the ﬁrst questions in such a list relates to the risk of a
disease in the future. Various types of information can help to
estimate the risk of disease (or disease susceptibility), and they can
range from relatively easily attainable types such as sex, age, and
ethnicity to sophisticated types such as imaging or genetic tests. For
example, women with a deleterious BRCA1 or BRCA2 mutation are
at increased risk of breast and ovarian cancer than other women.
Most questions in patient care, however, arise after disease has
occurred, and the simplest question is whether or not a person
actually has that particular disease. Population screening pro-
grams (using disease screening tests) focus on detecting disease,
especially potentially terminal illnesses, in early stages, often long
before there are any symptoms, because early detection can lead
to improved prognosis. Screening programs often use low-cost and
easily accessible diagnostic tools as a ﬁrst line of detection before
expensive, invasive, and possibly more accurate conﬁrmatory
diagnostic testing. Examples of screening tests include the Papa-
nicolaou test for cervical cancer, mammography for breast cancer,
and fecal occult blood tests and imaging tests such as sigmoido-
scopy and colonoscopy for colon and rectal cancer.
In contrast to screening for asymptomatic disease, other
questions about diagnosis arise after symptoms have occurred.Table 1 – Three deﬁnitions of personalized
medicine.
Deﬁnition
1
The use of combined knowledge (genetics, or
otherwise) about a person to predict treatment
response and thereby improve that person’s health
Deﬁnition
2
The use of combined knowledge (genetics, or
otherwise) about a person to predict disease
prognosis or treatment response and thereby
improve that person’s health
Deﬁnition
3
The use of combined knowledge (genetics, or
otherwise) about a person to predict disease
susceptibility, disease prognosis or treatment
response and thereby improve that person’s healthIn many cases, the differential diagnosis phase is a critical step in
determining how best to treat the patient. Consequently, much
time and energy has been spent on developing better ways to
make a diagnosis and a huge arsenal of diagnostic tests now exists
in medicine. While many of us may think of diagnostic tests as
ones that require special expertise or equipment (e.g., in vitro
diagnostics, imaging), technically speaking, any type of informa-
tion (including demographic information, parts of the medical
history, or results of a physical examination) can be regarded as a
potentially valuable diagnostic test [4].
It could be argued that the diagnosis is really only an
intermediate step in patient care and not an end goal. That is,
while it is useful to establish the diagnosis, attention should
really be directed at working out how to solve the problem, which
means developing the most effective and appropriate treatment
plan for an individual patient. With this focus in mind, other
questions arise such as will the patient recover spontaneously,
suffer temporary or permanent disability, or die from the dis-
ease? Questions such as these can be answered by using prog-
nostic tests, which help in choosing the optimal therapy or the
optimal window for therapeutic intervention on the basis of
disease severity. Ultimately, the aim of the therapy should be
to improve the prognosis. If the prognosis without therapy is
considered favorable, the clinician, together with the patient,
could opt to forgo therapy. This situation is found with Mam-
maprint, a test based on gene expression proﬁling that predicts
the risk of cancer recurrence within 5 to 10 years after the initial
diagnosis of breast cancer [5]. An example of the use of prog-
nostic testing to tailor the intensity of therapy is in acute myeloid
leukemia, where gene expression proﬁling has been used to
distinguish patients with a favorable (“low-risk”) prognosis and
patients with an unfavorable (“high-risk”) prognosis from
patients with an intermediate prognosis [6]. While gene expres-
sion proﬁling can be referred to as a parallel series of diagnostic
tests, its main practical value is to improve the accuracy of the
prognosis, thereby helping to improve treatment decision
making.
Another question that is closely related to prognosis is
whether or not a patient will respond favorably or unfavorably
to a particular drug. A companion diagnostic test can help to answer
this question before treatment has been initiated. A well-known
example of this kind of test is the HER2/neu test, which is used to
determine whether the drug trastuzumab (Herceptin)(a mono-
clonal antibody) is likely to be effective in treating a woman with
breast cancer [7]. That is, trastuzumab is effective only on tumors
with an overexpression of the HER2/neu-receptor, something
seen in approximately 15% to 20% of breast cancer cases. Other
companion diagnostic tests focus on predicting and thereby
avoiding serious adverse events caused by the therapy, while
other tests help to determine the optimal drug dose. Examples of
these types of tests are found in a later section. Because of their
ability to predict treatment outcomes, companion diagnostics are
sometimes referred to as predictive biomarkers [8]. In contrast to
prognostic tests, which give information about, predictive tests
describe those that give information about outcome regardless of
therapy (or at least information that is valid across a wide range
of available therapies). Predictive tests generally give information
about whether a particular patient’s disease will respond espe-
cially well to one treatment (vs. others). Therefore, predictive
tests are deﬁned in relation to a particular therapy.
Other questions in patient care arise after treatment has been
started. Is the treatment having the desired effect or should the
treatment plan be modiﬁed? The possible courses of action
available during treatment include continuing the therapy as
planned, modifying the frequency or dose, switching to another
therapy, and discontinuing all therapy. Clinicians can decide
which option is best by conducting various types of tests to
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causing serious adverse events, or if there are major changes in
the patient’s disease or general health status.
Last, after the patient has completed the entire treatment
regimen, there is a chance of disease recurrence even if the
patient is considered “disease free” or even “cured.” This is the
case with many types of cancer such as breast cancer or acute
leukemia. Because of this, patients who have had cancer in the
past will be followed up for a number of years to check for any
evidence of cancer, either locally or elsewhere in the body.What Kinds of Medical Tests Are Available?
The list of questions discussed above should make it clear that a
variety of different clinical questions exists. Fortunately, a
multitude of medical tests based on various technologies can
be performed to help us answer these questions. The middle part
of Figure 1 provides a short (and incomplete) list of the types of
technologies that these tests use. This list includes types of tests
based on demographics, patient history, and a physical exami-
nation, all of which have been used for centuries in the process
of differential diagnosis. In this process, even the simplest
type of information such as age, sex, and ethnic group can be
valuable, because they can be strongly associated with the
probability of a particular diagnosis. Besides the tests that have
been used for a long time, there are some relative newcomers
such as advanced imaging technologies (e.g., magnetic reso-
nance imaging) and so-called -omics technologies such as
genomics. Genomics is of particular signiﬁcance when it comes
to personalized medicine [1]. As noted earlier, the emergence of
the term personalized medicine coincided with the Human
Genome Project and other initiatives in that period, such as the
Single nucleotide polymorphism Consortium (a public–private
partnership of 10 large pharmaceutical companies and the
Wellcome Trust) for a reason, namely, the expectation that
greater knowledge of the human genome would enable us to
treat diseases much more effectively than ever before. For this
reason, most, if not all, deﬁnitions of personalized medicine refer
to the ability of genetic and genomic technology to “personalize”
treatment. Relativists, however, would argue that personalizedClinical question Type 
Disease susceptibility : what is the risk of developing a 
particular disease in the future?
Demo
history
exami
Screening: does a person have the disease? Histol
Diagnosis: what is the diagnosis? Clinica
Prognosis: what is the prognosis of a patient? Imagin
Companion diagnostic: will a particular patient respond 
favorably/unfavorably to a particular treatment?
genet
"-omic
(e.g., 
proteo
Monitoring: should treatment continue, be changed, or 
terminated? Are other treatments needed?
Other
Disease surveillance: has the disease recurred in one 
form or another?
Comb
listed 
Fig. 1 – Clinical questions, types of tecmedicine has existed since time immemorial and that genetic
knowledge holds great potential in further improving the quality
of personalized medicine.What Kinds of Medical Decisions Might Be Involved in
Personalized Medicine?
No test can make a patient better; something must take place
afterwards. For example, a test often informs treatment decisions
that ultimately make the patient better. The right-hand part of
Figure 1 shows a list of different medical decisions that can be
made. To start with, a clinician can use a test to decide whether
or not a patient will beneﬁt from a particular drug. As noted
earlier, the decision to use trastuzumab can be assisted by the
result of the HER2 test. A positive test result can be taken to mean
that trastuzumab will be sufﬁciently effective for that patient,
while a negative test result can be taken to mean that the
treatment will not be sufﬁciently effective. When the molecular
target of a drug is well deﬁned and speciﬁc to the causal pathway
of the disease, the combination of test-treatment may be referred
to as targeted therapy [9]. Because the action of these drugs is
different from that of traditional cytotoxic drugs used in medical
oncology, which nondiscriminately impair cell replication, the
expectation is that targeted therapies will be more speciﬁc for
inhibition of tumor growth and will have fewer side effects, for
applicable patients.
In other cases, a test can help determine whether the patient
will be more likely to have a serious adverse event after being
given a drug. An example of such a test can be found in patients
with epilepsy and other indications for carbamazepine [10].
Patients with HLA-B*1502 are more likely than other patients to
have dangerous skin reactions following carbamazepine therapy.
A HLA-B*1502 test before carbamazepine therapy can reduce the
frequency of these reactions. This type of test is a pharmacoge-
nomic test, a test that predicts how an individual will respond to a
drug on the basis of genetic information about that individual
and is usually based on pharmacokinetics or pharmacodynamics
[11]. Note that while some people also refer to the HER2 test as a
pharmacogenomic test, it is technically not true because that test
focuses on the genetic proﬁle of the tumor and not of the patient.of technology Medical decision
graphics, medical 
, lifestyle & physical
nation
1. Decision about drug use:
   a. one particular drug (yes or no)
      i. eligibility (effectiveness)
      ii. ineligibility (lack of safety)
   b. Decision about drug dosage
   c. Decision between drugs
ogy 2. Decision amongst different
medical treatments (e.g., drugs,
surgery, etc.)
l chemistry
g
ics and
s" technologies
genomics,
mics, metabolomics)
ination of the types
above
hnologies, and medical decisions.
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use, but rather about which dose to use. One example of a test
that helps to determine the optimal drug dosage involves therapy
with warfarin and other coumarin derivatives such as acenocou-
marol and phenprocoumon [12], which are prescribed for differ-
ent indications such as primary and secondary prevention of
deep vein thrombosis or pulmonary embolism, or the prevention
of systemic embolism or stroke in patients with prosthetic heart
valves or atrial ﬁbrillation. Treatment using these drugs is
challenging because there is large interindividual variation in
dose response and a narrow therapeutic window; an excessively
low dose increases the risk of thromboembolic events, while an
excessively high dose increases the risk of bleeding. Because
polymorphisms in CYP2C9 and VKORC1 are associated with
lower dose requirements and a higher risk of bleeding, knowl-
edge about the CYP2C9 and VKORC1 genotypes of a patient can
help to predict the optimal dosage before treatment is initiated
[13]. These kinds of tests can also be referred to as pharma-
cogenomic tests.
Companion diagnostic tests also can help to predict which of
the available drugs will be of greatest beneﬁt to an individual
patient. An example of this kind of test can be found in second-
line therapy of chronic myeloid leukemia, where the effective-
ness of candidate treatments such as dasatinib and nilotinib may
be predicted before initiating treatment [14].
Many other treatment decisions, however, involve not only
drugs but also other options such as surgery, radiotherapy, and
watchful waiting. Consider, for example, the treatment options
available to a woman at risk of breast cancer who has the BRCA1
gene. She could opt for a watchful waiting or surveillance
strategy, risk modiﬁcation (e.g., lifestyle modiﬁcation to reduce
her risks), chemoprevention, or even a radical mastectomy.
What Are Some Possible Deﬁnitions of Personalized Medicine?
All three dimensions discussed above (clinical questions, types
of technology, and medical decisions) relate to personalized
medicine. A commonly used example of personalized medicine
is the use of trastuzumab based on the HER2/neu test result to
treat breast cancer. It is therefore safe to say that the domain of
personalized medicine certainly includes companion diagnostic
tests that are intended to predict the effects of treatment before
treatment is initiated. As noted above, one can use these tests to
predict the degree of effectiveness, the chance of serious
adverse events, the optimal dose (to maximize effectiveness
and safety), and the best drug to use with a patient. Companion
diagnostic tests are so often used in the literature when people
describe examples of personalized medicine that we could even
base one deﬁnition of personalized medicine on them. A
possible formulation for this deﬁnition would be as follows: the
use of combined knowledge (genetics or otherwise) about a person to
predict treatment response and thereby improve that person’s health.
This ﬁrst deﬁnition is shown in Table 1. Others refer to
prognostic tests such as Oncotype Dx or Mammaprint when
they are asked to provide examples of personalized medicine
[11]. Oncotype Dx refers to a set of genomic tests that help to
estimate the prognosis of women with breast cancer. If a
woman has a relatively low chance of recurrence, adjuvant
chemotherapy may not be beneﬁcial. If this type of test, a
prognostic test, should be considered as part of personalized
medicine, then the deﬁnition needs to be expanded (see
Table 2). A possible formulation for this deﬁnition would be as
follows: the use of combined knowledge (genetics or otherwise) about a
person to predict disease prognosis or treatment response and thereby
improve that person’s health. Finally, others include disease
susceptibility tests such as BRCA testing when they describe
personalized medicine. For example, the deﬁnition ofpersonalized medicine provided by the President’s Council
explicitly includes disease susceptibility, while the deﬁnition
used by the US National Cancer Institute refers to disease
prevention, which can be achieved only by examining disease
susceptibility [1,3]. If this type of test should also be included in
the deﬁnition of personalized medicine, a possible formulation
for this deﬁnition would be as follows: the use of combined
knowledge (genetics or otherwise) about a person to predict disease
susceptibility, disease prognosis, or treatment response and thereby
improve that person’s health.Examples of What Could Be Viewed as Personalized Medicine
Table 2 provides some examples of how genetic or genomic tests
are used in clinical care to improve decision making. It should be
clear that the result of a test can be used in different ways. Note
the clear biologically based link between the companion diag-
nostic tests and the decision about the use or dosage of the
medicine. Companion diagnostics make it possible to maximize
treatment response (by means of targeted therapy) and minimize
the risk of adverse events (by means of pharmacogenomic tests).
A prognostic test, by predicting the future without chemotherapy,
can inform the decision regarding whether to proceed with
chemotherapy. A test with high prognostic value not only helps
to improve treatment decisions now but may also hold valuable
information about how to develop targeted therapy in the future.
The same holds true for a disease susceptibility test. One could
argue that the prognostic and disease susceptibility tests repre-
sent an intermediate form of personalized medicine, because a
biologically based direct link between the test and a therapy has
not yet been developed.
One other comment to make here is that the treatment
response monitoring is not considered as a type of personalized
medicine according to any of the three deﬁnitions given above. At
present, many would not consider treatment response monitor-
ing as part of the domain of personalized medicine, although
some have implied otherwise [9]. Regardless of this issue of
labeling, it is clear that response monitoring tests (for both
effectiveness and safety) can play a valuable role in improving
the effectiveness and cost-effectiveness of patient care. A later
section examines this in more detail.Personalized Medicine Utilizes a Mix of Technologies
While genetic or genomic information can be extremely valua-
ble in improving medical decisions such as determining
whether or not a patient is a good candidate for a particular
drug, one should not underestimate how often other informa-
tion (such as comorbidity, concomitant medication, or even
patient preferences) is applied when making treatment deci-
sions. In other words, ﬁnal treatment decisions are not just
based on the results of a genetic or genomics test alone. More-
over, estimates of disease susceptibility or disease prognosis can
be improved by combining genomic test results with knowledge
about various factors such as age, lifestyle, or tumor size.
Indeed, such combinatorial algorithms may be essential when
predicting disease susceptibility, disease prognosis, or drug
response of an individual patient. A classic example of a
prediction tool that combines various types of information is
the Framingham risk equation to estimate the risks of various
types of cardiovascular outcomes among individuals at risk of
cardiovascular disease [15]. The frequent need to combine
information to improve predictive ability is the reason why all
the deﬁnitions for personalized medicine proposed above refer
to “the combined knowledge (genetics or otherwise)” to improve
health outcomes.
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Many people would assume that personalized medicine is
personalized, simply because of the word “personalized.” Is this
really the case? While the Wikipedia deﬁnition focuses on the
individual patient, the President’s Council explicitly refers to
subpopulations and not to individual patients. In contrast, the
National Cancer Institute deﬁnition does not clarify whether or
not personalized medicine focuses on the individual or on a
subpopulation. What conclusions can we draw if we look at
widely used examples of personalized medicine? If we look at
the HER2-trastuzumab application, we see that a subgroup of
women with early breast cancer have a tumor that is HER2-
positive. As a result, this subgroup is eligible for trastuzumab,
which is effective for HER2-positive tumors. Because all the
women in this subgroup, however, receive trastuzumab in the
same way (e.g., same dosage regimen), many view this as an
example of subgroup medicine or stratiﬁed medicine [16]. The
President’s Council acknowledges this and goes one step further
by explicitly stating that this form of medicine is still classiﬁable
as personalized medicine. Therefore, the purist may conclude
that most current examples of personalized medicine are not
truly personalized. Depending on one’s viewpoint, one can
claim either that personalized medicine is not really here yet
or adopt a more liberal deﬁnition of personalized medicine and
claim that it is. The deﬁnitions provided above accommodate
both viewpoints because no explicit distinction is made between
personalized and stratiﬁed medicine.
Personalized Medicine or Personalized Health Care?
Another term that has emerged in recent years is personalized
health care. How can we distinguish personalized medicine
from personalized health care? One approach would be to say
that personalized health care extends beyond the boundaries of
personalized medicine to address questions relating to treat-
ment monitoring and disease surveillance, the last two clinical
questions shown in Figure 1. For example, Gellad et al. [17]
examined the cost-effectiveness of treating chronic hepatitis C
by using a response-guided approach where response to treat-
ment was measured by using viral RNA. While they referred to
this approach as personalized therapy, others such as Roche [18]
see this as an example of personalized health care. Moreover,
Roche also regards the HER2 test as an example of personalized
health care, thereby suggesting that personalized medicine is a
subset of personalized health care. Interestingly, the current
deﬁnition provided by Wikipedia for personalized medicine
shown earlier would then seem to be a deﬁnition for personal-
ized health care [2]. Another source views personalized health
care in a different way and states that “personalized medicine
refers speciﬁcally to the use of genetics and genomic” and goes
on to add that they “view personalized health care as a broader
platform that includes genetics and genomics but also includes
any other biologic information that helps predict risk for disease
or how a patient will respond to treatments” [19]. It therefore
seems safe to say that the deﬁnition of personalized health care
used by a person is dependent on the deﬁnition of personalized
medicine that they use!Discussion
Personalized medicine is a term used by many to say different
things, and there are at least three important reasons for disagree-
ment about its deﬁnition. First, there is the issue about whether or
not personalized medicine always has a genetic or genomic
component. Second, there is disagreement about whether person-
alized medicine focuses only on the optimal use of medicines (see
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Third, there is the issue about whether personalized medicine really
just means stratiﬁed medicine. These disagreements make it impos-
sible to provide one precise deﬁnition for personalized medicine. The
deﬁnitions provided in this article, however, have been formulated in
such a way that they may be accepted by the majority.
Some would say that the ultimate goal of either personalized
medicine or personalized health care is to provide “the right treat-
ment to the right patient at the right time”; a variation of this is
“therapy with the right drug at the right dose in the right patient”
[20]. It would be folly to say that this goal can be achieved without
considering “nonmedical factors” such as patient preferences and
psychosocial factors. After all, who truly believes that genetics,
genomics, and other -omics technologies should be—or will be—
the only basis for treatment decisions? As noted above, genetics will
always be combined with other information to determine the
disease susceptibility, disease prognosis, and treatment response
of an individual. More importantly, the best way to prevent or treat
disease in an individual will depend on many factors and not just
genetics. Nevertheless, there is much to be gained from innovation
in the –omics ﬁelds. The Human Genome Project ushered in a new
era in the effort to prevent and treat disease [1]. While the term
personalized medicine was given new meaning at a time when
projects such as the Human Genome Project began, our ability to
personalize medicine will continue to advance in unimaginable
ways as we come to learn more about the heterogeneity that exists
among individuals and current diseases. For this reason, it is
possible that the deﬁnition of personalized medicine will evolve as
new discoveries are made. For now, the most appropriate deﬁnition
for personalized medicine is perhaps the third and broadest of the
three introduced earlier: the use of the combined knowledge (genetic
or otherwise) about a person to predict disease susceptibility,
disease prognosis, or treatment response and thereby improve that
person’s health.
One last footnote to add in closing. As of February 17, 2013, a
PubMed search of “personalized medicine” yielded 2841 hits. The
oldest of these hits was a reference to an article titled “Can
personalized medicine survive?” by C.M. Gibson in the journal
Canadian Family Physician in 1971, who lamented the difﬁculty of a
general practitioner in keeping up with all the changes in medicine,
including both the health care system and new technologies [21]. In
his article, he noted that “we live in times of great change and it
would probably be true to say that within the span of a single
lifetime, medicine has left medievalism behind it.” While the
immediate response would be to say that we did indeed see a great
deal of change in the 20th century, the question we must ask
ourselves is what kinds of change await us in the next decades?
All in all, we can debate about the best deﬁnition for terms such as
personalized medicine, but every new development will likely force
us to reformulate that deﬁnition.
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